EDA2R (ectodysplasin A2 receptor) is an X-linked transmembrane receptor that mediates activation of non-canonical and canonical NF-κB and JNK signaling pathways through binding to TRAF3 and TRAF6 1. The receptor specifically recognizes the EDA-A2 ligand isoform and is involved in ectodermal development and epidermal differentiation. Clinically, EDA2R has emerged as a central regulator in multiple disease states. Genetic variants in the EDA2R locus on the X-chromosome X a major genetic risk factor for androgenetic alopecia 2. More significantly, EDA2R-NIK signaling drives cancer-associated muscle atrophy through non-canonical NF-κB pathway activation; tumor-derived oncostatin M upregulates muscle EDA2R expression, and genetic deletion of EDA2R or NIK protects mice from cancer cachexia 3. Beyond cachexia, elevated EDA2R expression correlates with aging, inflammaging, and numerous age-related diseases including cardiovascular disease, dementia, Parkinson's disease, obesity, and diabetes 1. EDA2R also promotes muscle glucose intolerance and sarcopenia in aging and denervation contexts 4. Plasma EDA2R protein levels predict peripheral artery disease risk in type 2 diabetes patients 5. These findings identify EDA2R as both a biomarker of aging and active driver of catabolic processes, making it a promising therapeutic target for muscle wasting diseases and age-related pathologies.